BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Idiopathic pulmonary fibrosis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for idiopathic pulmonary fibrosis: 54 (41 sponsors; 17 newly posted in the last 180 days, 3 stopped in the last 180 days; 11 new-entrant sponsors). Momentum score 23.1, rank 17 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 5, Phase 2 31, Phase 3 13, Phase 4 0, N/A 3.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 3 | P3 2, NA 1 | 1 | 0 |
| Trevi Therapeutics TRVI new entrant | 2 | P3 2 | 2 | 0 |
| Boehringer Ingelheim | 3 | P2 2, P3 1 | 1 | 2 |
| Haisco Pharmaceutical Group Co., Ltd. | 3 | P2 2, P3 1 | 1 | 0 |
| InSilico Medicine Hong Kong Limited | 2 | P2 1, P3 1 | 1 | 0 |
| PureTech PTCHF | 2 | P3 1, P2 1 | 0 | 0 |
| Sunshine Lake Pharma Co., Ltd. SBFM | 2 | P2 1, P3 1 | 0 | 0 |
| Beijing Tide Pharmaceutical Co., Ltd | 1 | P3 1 | 0 | 0 |
| Guangzhou JOYO Pharma Co., Ltd | 1 | P3 1 | 0 | 1 |
| Shanghai Ark Biopharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| United Therapeutics UTHR | 1 | P3 1 | 0 | 0 |
| Avalyn Pharma Inc. AVLN | 2 | P2 2 | 0 | 1 |
| Chiesi Farmaceutici S.p.A. | 2 | P1 1, P2 1 | 1 | 0 |
| Shanghai Synvida Biotechnology Co.,Ltd. | 2 | P2 1, EARLY_P1 1 | 0 | 2 |
| AbbVie ABBV | 1 | P2 1 | 0 | 0 |
| Agomab Spain S.L.U. new entrant | 1 | P2 1 | 1 | 0 |
| AstraZeneca AZN new entrant | 1 | P2 1 | 1 | 0 |
| Calluna Pharma AS | 1 | P2 1 | 0 | 0 |
| Contineum Therapeutics CTNM | 1 | P2 1 | 0 | 0 |
| Cosmos Rx, Inc COSG new entrant | 1 | NA 1 | 1 | 0 |
| Cough Monitoring Medical Solutions | 1 | NA 1 | 0 | 0 |
| CSPC-NBP Pharmaceutical Co., Ltd. new entrant | 1 | P2 1 | 1 | 0 |
| Cumberland Pharmaceuticals CPIX | 1 | P2 1 | 0 | 0 |
| Daewoong Pharmaceutical Co. LTD. | 1 | P2 1 | 0 | 0 |
| Dragonboat Biopharmaceutical Company Limited | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Trevi Therapeutics, Shanghai Ark Biopharmaceutical Co., Ltd., Agomab Spain S.L.U., AstraZeneca, Cosmos Rx, Inc, CSPC-NBP Pharmaceutical Co., Ltd..
Recently stopped trials
- NCT06360094 Boehringer Ingelheim - terminated: A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary
- NCT06317285 GlaxoSmithKline - terminated: The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- NCT06097260 Pliant Therapeutics, Inc. - terminated: DSMB recommendation Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05139719 A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Dis | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | recruiting | 110 |
| 2026-12 est. | P2 | Avalyn Pharma Inc. AVLN | NCT07194382 AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Idiopathic Pulmonary Fibrosis (IPF) | recruiting | 160 |
| 2026-12 est. | P2 | Pulmovant, Inc. | NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovas | recruiting | 20 |
| 2026-12-31 est. | P2/P3 | Guangzhou JOYO Pharma Co., Ltd | NCT06125327 SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | recruiting | 210 |
| 2026-12-31 est. | P2 | Shanghai Synvida Biotechnology Co.,Ltd. | NCT07121413 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis(IPF) | recruiting | 48 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Calluna Pharma AS | NCT06736990 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | active not recruiting | 150 |
| 2026-10-31 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07019090 Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | not yet recruiting | 120 |
| 2026-10-13 est. | P2 | Daewoong Pharmaceutical Co. LTD. | NCT05389215 Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | Idiopathic Pulmonary Fibrosis | active not recruiting | 102 |
| 2026-10-06 est. | P3 | Bristol-Myers Squibb BMY | NCT06003426 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | active not recruiting | 1255 |
| 2026-08-27 | P2 | Syndax Pharmaceuticals SNDX | NCT06132256 MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | completed | 145 |
| 2026-08-21 | P2 | Endeavor Biomedicines, Inc. | NCT06422884 A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) | Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease | completed | 213 |
| 2026-08-05 | P2 | Boehringer Ingelheim | NCT06241560 A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood | Idiopathic Pulmonary Fibrosis | completed | 20 |
| 2026-07-21 | P2 | SPARK Biopharma SPKLF | NCT06747923 SB17170 Phase 2 Trial in IPF Patients | IPF; Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) | completed | 32 |
| 2026-05-26 | P2 | Pulmovant, Inc. | NCT06635850 A Study of Mosliciguat in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease; Lung Diseases; Vascular Diseases; Cardiovascular | active not recruiting | 135 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "idiopathic pulmonary fibrosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.